Search PubMed⌕ Search

Biomedical subjects

H M Lachman

Publications and source records attributed to H M Lachman.

At least 37 records · Page 2Linked to original sources
PubMed1996

Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome.

Velo-cardio-facial-syndrome (VCFS) is a common congenital disorder associated with typical facial appearance, cleft palate, cardiac defects, and learning disabilities. The majority of patients have an interstitial deletion on chromosome 22q11. In addition to physical abnormalities, a variety of psychiatric illnesses have been reported in patients with VCFS, including schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder. The psychiatric manifestations of VCFS could be due to haploin-sufficiency of a gene(s) within 22q11. One candidate that has been mapped to this region is catechol-O-methyltransferase (COMT). We recently identified a polymorphism in the COMT gene that leads to a valine-->methionine substitution at amino acid 158 of the membrane-bound form of the enzyme. Homozygosity for COMT158met leads to a 3-4-fold reduction in enzymatic activity, compared with homozygotes for COMT158val. We now report that in a population of patients with VCFS, there is an apparent association between the low-activity allele, COMT158met, and the development of bipolar spectrum disorder, and in particular, a rapid-cycling form.

Abnormalities, Multiple↗
PubMed1996

Modulation of learned helplessness by 5-hydroxytryptamine2A receptor antisense oligodeoxynucleotides.

Serotonergic systems have been implicated in the pathogenesis of major depression in humans as well as in learned helplessness (LH), an animal model of depression. To understand the significance of neuronal responses in depression and LH that are mediated by serotonin (5-hydroxytryptamine, 5HT) receptors, we used intracerebroventricular injections to introduce a unique antisense oligonucleotide (ASO) to the 5HT2A receptor and determined its effect on LH behavior in Sprague-Dawley rats as determined by an escape-avoidance strategy. Of the rats injected with the 5HT2A receptor ASO, 8/16 rats met criteria for LH. By contrast, only 1/15 of the control group injected with 5HT2A sense oligonucleotide (SO) met criteria for LH. Quantitative receptor autoradiography revealed significant differences in 5HT2A receptor density between ASO and control sense oligonucleotides (SO), in close proximity to the injection site. Significant decreases in 5HT2A receptor density caused by oligonucleotide blockade were found in the CA3 hippocampal region. These data support the view that central 5HT, mediated by the 5HT2A receptor, participates in regulating behaviors that are affected by inescapable stress, and that the induction of behavioral depression may be specifically regulated via serotonergic pathways that terminate in this hippocampal subfield.

Animals↗
PubMed1996

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

Catechol-O-methyltransferase (COMT) inactivates catecholamines and catechol drugs such as L-DOPA. A common genetic polymorphism in humans is associated with a three-to-four-fold variation in COMT enzyme activity and is also associated with individual variation in COMT thermal instability. We now show that this is due to G-->A transition at codon 158 of the COMT gene that results in a valine to methionine substitution. The two alleles can be identified with a PCR-based restriction fragment length polymorphism analysis using the restriction enzyme Nla III. The identification of a gentic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur, including mood disorders, schizophrenia, obsessive compulsive disorder, alcohol and substance abuse, and attention deficit hyperactivity disorder. In addition, this polymorphism may have pharmacogenetic significance in that it will help make it possible to identify patients who display altered metabolism of catechol drugs.

Catechol O-Methyltransferase↗
PubMed1995

A molecular model for bipolar affective disorder.

The biological basis of bipolar disorder is not known. Models for the illness have been proposed that were based on the neurobiological effects of pharmacological agents that affect mood. Although of great interest, these models have not adequately explained the striking clinical pattern of illness in which patients may experience either unipolar episodes or bipolar cycles of mania and depression. We now present a new model suggesting that the unique clinical heterogeneity found in patients with bipolar disorder could be explained by a defect in a 'downstream' portion of a signal transduction pathway that can regulate two or more neurotransmitter systems that have opposite effects on neuronal activity. This model may target specific candidate genes for involvement in bipolar disorder.

Bipolar Disorder↗
PubMed1993

Effects of the antiglucocorticoid RU 38486 on the induction of learned helpless behavior in Sprague-Dawley rats.

Learned helplessness (LH) is induced by exposure to an inescapable or uncontrollable stressor which results in an inability to escape or avoid the same stressor when subsequently presented in a different context. In order to understand which central mechanisms may influence the expression of the learned helpless phenotype, we have pursued an experimental approach that seeks to elucidate the behavioral effects of glucocorticoid (GC) hormones in this animal model of depression. We have previously shown that the induction of LH behavior is enhanced by adrenalectomy, an effect that is reversed by corticosterone. In this study, our aim was to attempt to locate CNS sites responsible for the observed effects of glucocorticoids on learned helpless behavior by introducing the type II GC receptor antagonist, RU 38486 to discrete brain regions. We did not observe a significant effect in LH with acute systemic, acute dentate gyrus or intracerebroventricular injection of RU 38486 in contrast to previous studies using the Porsolt swim test, another animal model of depression. However, we were able to observe a significant change upon chronic administration to the dentate gyrus. These findings suggest that glucocorticoids exert a long-term influence on stress-induced behavior, presumably by affecting glucocorticoid responsive genes in the dentate gyrus.

Animals↗
PubMed1993

Alterations in glucocorticoid inducible RNAs in the limbic system of learned helpless rats.

Glucocorticoids (GC) have an important effect on mood in humans and influence learned helplessness, an escape avoidance paradigm that is considered one of the best animal models of depression. A strong genetic component underlies the development of learned helplessness as shown by the emergence of a line of highly vulnerable rats (LH strain) through selective inbreeding. In addition, hormonal factors play a role. Adrenalectomy (adx) for example is known to increase the vulnerability to acquire learned helplessness, an effect that is reversed by glucocorticoids (GC). Since GC function primarily by modulating gene expression, hormone mediated alterations in mRNAs expressed in the brain may be important in the development of an adequate escape avoidance response. Conversely, we postulate that the deficit in escape avoidance behavior exhibited by the LH strain may be associated with an alteration in GC-mediated gene expression in the brain. To test this hypothesis, we analyzed GC-responsive mRNAs that are expressed in the hippocampus. Control Sprague-Dawley (SD) rats showed consistent alterations in mRNAs that are modulated by GC, such as type II GC receptor (GR) and metallothionein-1 (MT-1). Under our experimental conditions, both GR and MT-1 mRNA are significantly increased in the hippocampus of hormone-treated SD rats. An increase in hypothalamic GR mRNA was also observed. However, under the same experimental conditions, LH rats showed more selective hormone induced changes since GC had no effect on hypothalamic and hippocampal GR mRNA whereas a significant increase in MT-1 mRNA was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenalectomy↗
PubMed1992

Hippocampal neuropeptide Y mRNA is reduced in a strain of learned helpless resistant rats.

The learned helpless rat is considered to be one of the better animal models of depression. A genetically inbred strain with a high vulnerability to develop helplessness (LH), as well as a highly resistant strain (NLH) have both been developed. Since the brain peptide neuropeptide Y (NPY) is involved in the regulation of a number of behaviors known to be altered in clinical depression as well as in learned helplessness, we measured the relative level of NPY mRNA in the hippocampus and cortex of control Sprague Dawley (SD), LH and NLH rats. We find that NLH rats have approximately a 30-35% decrease in basal hippocampal NPY mRNA compared with SD and LH rats. By contrast, cortical NPY mRNA and hippocampal pre-proenkephalin and somatostatin mRNA levels were not significantly different in the 3 strains. The data suggest that the regulation of NPY gene expression may be involved in the reduced vulnerability of NLH rats to develop learned helplessness.

Amino Acid Isomerases↗
PubMed1992

Acute lithium treatment enhances neuropeptide Y gene expression in rat hippocampus.

It has been suggested that the therapeutic action of lithium in affective disorders may be due to its inhibition of signal transduction and second messenger synthesis, in particular of the phosphoinositide (PI) pathway. Yet, previous work in neuronal cell lines indicates that lithium has an enhancing effect on gene expression mediated by protein kinase C, which is activated by the PI pathway. In this report, we have analyzed the effect of lithium on two neuropeptide encoding genes that are regulated by second messenger systems; neuropeptide Y (NPY) and proenkephalin (Enk). We find that acute treatment with lithium, resulting in serum levels that are within the therapeutic range effective in patients with mood disorders, significantly enhances basal expression of the NPY gene in rat hippocampus. In contrast, no effect on Enk expression was detected. This selective effect in a limbic structure supports the hypothesis that gene expression may be an important target of lithium's therapeutic action.

Animals↗
PubMed1991

Lithium augments pilocarpine-induced fos gene expression in rat brain.

Lithium salts are considered the most effective agents used in treating manic-depression. Previous studies in PC12 pheochromocytoma cells indicate that lithium has a dramatic augmenting effect on expression of the fos proto-oncogene, a component of the AP-1 transcription factor. Although fos expression is activated by agonists that function through different signal transduction pathways, the lithium augmenting effect appears to be specific for receptor and post-receptor stimulators of protein kinase C (PKC). In particular, fos induction mediated by the m1 muscarinic receptor linked to PKC activation was found to be exquisitely sensitive to lithium enhancement. We now show that a similar augmenting effect can be demonstrated in rat brain. Following treatment with the muscarinic agonist pilocarpine, fos mRNA accumulates in the cortex, an effect that is blocked by the m1 antagonist pirenzepine. Rats treated with a single intraperitoneal injection of lithium chloride exhibited a substantial increase in pilocarpine-mediated fos expression. In contrast, fos expression induced in several brain regions by a single electroconvulsive shock is not augmented by lithium. The finding that short-term treatment with lithium enhances fos expression in the brain suggests a mechanism for its therapeutic action.

Animals↗
PubMed1991

Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action.

Lithium salts are the most effective agents used in treating manic-depressive illness. It has been suggested that lithium's therapeutic efficacy could be due to an inhibitory effect on either inositol phospholipid (IP) and/or cyclic nucleotide metabolism. We have investigated the effect of lithium on these two signal transduction pathways in PC12 pheochromocytoma cells by studying a common effector target, expression of the fos protooncogene. We find that lithium, at therapeutic doses, has an augmenting effect on phosphatidylinositol (PI)-mediated fos expression induced by activating a muscarinic cholinergic pathway, whereas it has no effect, at tenfold the therapeutic dose, on fos expression induced by receptor or postreceptor activators of cyclic adenosine monophosphate (cAMP). The lithium augmenting effect is also observed when the cells are treated with phorbol esters, which directly activate protein kinase C (PKC), suggesting that the level of lithium's interaction with the IP pathway is at the postreceptor level. We also show that phorbol esters induce extensive down regulation of subsequent cholinergic and phorbol ester responsiveness as well as heterologous down regulation of cAMP responses. Treatment of down-regulated cells with lithium leads to an enhanced responsiveness when cells are rechallenged with agonists that activate PKC but not by agonists that stimulate cAMP. We also show that carbamazepine, another antimanic agent, has an inhibitory effect on cAMP-mediated fos but no effect on the IP pathway. The opposite effects of lithium and carbamazepine on two critical transducing systems suggest a model for the antimanic action of these agents.

Adrenal Gland Neoplasms↗
PubMed1990

Lithium augments fos protoonocogene expression in PC12 pheochromocytoma cells: implications for therapeutic action of lithium.

It has been proposed that lithium's antimanic action is due to an effect on phosphoinositide metabolism. Second messengers generated by this pathway regulate calcium mobilization and the activity of the serine and threonine kinase, protein kinase C (PKC). Included among the targets of PKC is activation of fos protooncogene expression, a well-established component of the AP-1 transcription factor. Because of these interactions, we investigated the effect of lithium on fos gene expression in PC12 pheochromocytoma cells. We find that lithium increases the level of fos mRNA that occurs in response to receptor and postreceptor activation of PKC. Treatment with lithium also leads to an augmentation of muscarinic cholinergic-mediated fos gene expression in cells that are down-regulated as a result of excessive cholinergic stimulation. The ability of lithium to enhance the response of a down-regulated cholinergic system suggests a model for its therapeutic efficacy in affective disorders.

Adrenal Gland Neoplasms↗
PubMed1989

Abnormal signal transduction: a hypothetical model for bipolar affective disorder.

The molecular basis of bipolar affective disorder is poorly understood at this time. The episodic nature of the condition in which relatively euthymic periods of variable duration separate periods of mania and depression, and the specificity of lithium therapy suggests that a molecular target of the illness may be a system that bidirectionally influences neurotransmission and is affected by lithium. Signal transduction pathways, which are important mediators of neurotransmitter generated signals, may represent such a system because they: 1) generate second messenger molecules that stimulate neurotransmission and also mediate negative feedback mechanisms, and 2) appear to be a direct target of lithium's action on cells. In this paper, we present a model in which abnormal regulation of signal transduction could lead to the episodic accumulation of biologically active transducers or second messengers. These alterations may result in prolonged effector stimulation which may underlie mania, followed by excessive receptor desensitization, which may result in depression. Using our model we suggest a plausible hypothesis that can explain the clinical spectrum of the disorder and the therapeutic action of lithium.

Bipolar Disorder↗
PubMed1989

Development of H+ secretion by cultured renal inner medullary collecting duct cells.

The purpose of these studies was to characterize the development of H+ secretion by cultured inner medullary collecting duct (IMCD) cells. Differentiated IMCD cells derived from rat papillae develop in culture N-ethylmaleimide (NEM)- and dicyclohexylcarbodiimide (DCCD)-sensitive Na+-independent H+ pump, but showed substantial heterogeneity. Cells with pHi greater than or equal to 7.1, measured by 2',7'-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF), showed more H+ pumping than did those with pHi less than 7.1. Quiescent cells in domes and in the center of growing nests often showed active H+ pumping activity, but rarely exhibited Na+-H+ exchange, whereas dividing cells at the periphery of the nests showed only Na+-H+ exchange. Differentiated IMCD cells also showed Na+-independent 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS)-sensitive Cl(-)-HCO3- exchange that functioned best when pHi was greater than or equal to 7.1, and homogenates of IMCD cells expressed carbonic anhydrase (CA) activity and CA II mRNA. A subgroup of IMCD cells avidly bound fluorescent peanut agglutinin (PNA); this binding became more extensive with time in culture. The PNA-labeled cells showed increased BCECF uptake, higher pHi, and more H+ pumping activity than did cells not binding PNA. They could be isolated by gel-immobilized PNA and in culture showed more CA activity and H+ pumping activity than unselected monolayers. The percentage of cells binding PNA correlated well with CA activity, indicating that this subgroup is better specialized to secrete H+. The appearance of PNA binding sites and the development of high CA activity may be characteristic of IMCD cell differentiation in culture.

Animals↗
PubMed1989

c-myc protooncogene expression in mouse erythroleukemia cells.

Murine erythroleukemia (MEL) cells are erythroid progenitors whose programs of erythroid differentiation has been interrupted by transformation with the Friend virus complex. As a result of the ability of certain chemicals such as dimethylsulfoxide (DMSO) to induce terminal erythroid differentiation, the cells have been used as a model for understanding the molecular basis of cellular differentiation. Recent work on MEL cells as well as other differentiating systems indicates that expression of cellular protooncogenes is implicated in chemically mediated differentiation. In MEL cells the expression of the c-myc protooncogene undergoes unusual biphasic changes following inducer treatment. Levels of c-myc mRNA decrease 10- to 20-fold between 1 and 2 hr and are then reexpressed between 12 and 24 hr. These changes occur as a result of complex transcriptional and posttranscriptional regulatory events. Recent DNA transfection experiments, in which MEL cells were transfected with myc expression vectors, indicate that both the early decrease in c-myc expression and its subsequent reexpression are important events in the differentiation pathway. The work on MEL cells, as well as on other models of differentiation, is directed at understanding the molecular basis of leukemogenic transformation and cellular differentiation. The ability of c-myc, as well as other protooncogenes, to influence both of these events indicates that cellular protooncogenes play a central role in their regulation.

Animals↗
PubMed1987

Contributions of transcriptional and post-transcriptional mechanisms to the regulation of c-myc expression in mouse erythroleukemia cells.

Chemically induced differentiation of mouse erythroleukemia (MEL) cells leads to complex changes in c-myc mRNA levels. Within 1-2 hr after the addition of the inducer hexamethylene bisacetamide (HMBA), c-myc mRNA levels decrease 10- to 20-fold and remain low until 12-24 hr, at which time the mRNA reaccumulates to its original level. Thereafter as the cells undergo terminal differentiation, c-myc mRNA again declines to a low level. We have investigated the regulation of these changes by measuring c-myc gene transcription and mRNA turnover. We find that the early rapid decline in c-myc mRNA is due to an increase in the block to elongation of transcription within the c-myc first exon. Effective c-myc transcription is then restored after 2 hr of HMBA treatment to the level present in uninduced cells and is maintained throughout the remainder of the differentiation program. These results demonstrate that, except for the rapid decline in c-myc mRNA immediately following inducer treatment, all subsequent regulation of message levels occurs through post-transcriptional mechanisms. Studies of c-myc mRNA turnover suggest that some post-transcriptional regulation is nuclear.

Acetamides↗
PubMed1986

Transfection of mouse erythroleukemia cells with myc sequences changes the rate of induced commitment to differentiate.

We have examined the role of the c-myc protooncogene in chemically induced differentiation of mouse erythroleukemia (MEL) cells by transfecting the cells with recombinant plasmids in which c-myc coding sequences were cloned downstream from the mouse metallothionein I promoter in sense and antisense orientations. We previously showed that treatment of MEL cells with inducers of differentiation leads to a rapid (less than 2 hr) decrease in the level of c-myc mRNA. c-myc mRNA is then transiently restored to pretreatment levels approximately 12-18 hr later. These events occur prior to the detection of cells that are irreversibly committed to erythroid differentiation. MEL cell transfectants containing the plasmid with myc in the sense orientation express a chimeric MT-myc mRNA, which also decreases shortly after addition of inducer. However, these clones reexpress myc RNA more rapidly than the parental line and they also differentiate more rapidly. On the other hand, transfectants containing the plasmid with myc in the antisense orientation exhibited a delay in the reexpression of c-myc mRNA and were found to differentiate more slowly than parental cells. Thus, we find a correlation between the time at which myc RNA is reexpressed following inducer treatment and the rate of entry of cells into the terminal differentiation program.

Acetamides↗
PubMed1985

c-myc mRNA levels in the cell cycle change in mouse erythroleukemia cells following inducer treatment.

Several lines of evidence suggest that the c-myc protooncogene is involved in some aspect of cell division in mammalian cells. We have been investigating changes in the expression of c-myc mRNA in mouse erythroleukemia cells during chemically induced terminal erythroid differentiation. In vitro induction of erythroleukemia cell differentiation results in a switch from cells with unlimited proliferative capacity to cells that undergo a small number of terminal cell divisions. The level of c-myc mRNA changes rapidly following treatment with inducing agents. After a very rapid decline the mRNA is restored to pretreatment levels and then declines again. We have now measured the level of c-myc mRNA with respect to position in the cell cycle. Prior to inducer treatment the level of c-myc mRNA is relatively constant throughout the cell cycle. However, when the mRNA is restored following treatment with hypoxanthine or hexamethylenebisacetamide, it is found primarily in cells in the G1 phase. Thus, treatment with inducers of differentiation leads to a change in the cell cycle regulation of c-myc mRNA. This change may be involved in the altered proliferative capacity of the cells that occurs during terminal differentiation.

Animals↗